Article RDF
pages:- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- 99
- 100
- 101
- 102
- 103
- 104
- 105
- 106
- 107
- 108
- 109
- 110
- 111
- 112
- 113
- 114
- 115
- more...
- Lingual nerve impairment/injury after retrieval of the displaced mandibular third molar into the floor of the mouth
- Linking Outcomes, Cost-Effectiveness, and Reimbursement for Vascular Intervention: The Train Is Leaving the Station
- Links between donor macrosteatosis, interleukin-33 and complement after liver transplantation.
- Lipemic Arthropathy Simulating Septic Arthritis in a Patient with Severe Necrotizing Pancreatitis: A Case Report
- Lipid Control in the Modern Era An Orphan's Tale of Rags to Riches
- Lipid Formulations of Amphotericin B Significantly Improve Outcome in Solid Organ Transplant Recipients with Central Nervous System Cryptococcosis
- Lipid intervention in diabetes, metabolic syndrome and beyond
- Lipoprotein(a) in clinical practice: A guide for the clinician
- Liposomal Bupivacaine Transversus Abdominis Plane Blocks in Laparoscopic Colorectal Resections: A Single-Institution Randomized Controlled Trial
- Lipoxin concentration in high-risk participants taking aspirin: a potential mechanism of action
- Lipoxins are correlated with inflammatory milieu in low-risk pregnancies
- LIRAGLUTIDE ACHIEVES A1C TARGETS MORE OFTEN THAN SITAGLIPTIN OR EXENATIDE WHEN ADDED TO METFORMIN IN PATIENTS WITH TYPE 2 DIABETES AND A BASELINE A1C < 8.0%
- Liraglutide achieves HbA1c targets more often than sitagliptin or exenatide when added to metformin in patients with Type 2 diabetes and a baseline HbA1c < 8.0%
- Liraglutide as add-on to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes: a 26-week, randomised, double-blind, placebo-controlled trial
- Liraglutide as add-on to sodium-glucose co-transporter-2 inhibitors in patients with inadequately controlled type 2 diabetes: LIRA-ADD2SGLT2i, a 26-week, randomized, double-blind, placebo-controlled trial
- Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)
- Liver Disease Management TeleECHO Improves Provider Knowledge and Care of Patients
- Liver needle biopsies and prediction of histologic tumor grade for midgut neuroendocrine tumors.
- Liver Needle Biopsies Are Poor Predictors of Histologic Tumor Grade for Midgut Neuroendocrine Tumors
- LIVER TRANSPLANT BILIARY MISMATCH: BILIARY TRANSPOSITION VS DUCTOPLASTY
- Liver Transplantation (OLT) Utilizing Donation after Cardiac Death (DCD) Allografts: A Single Center Experience
- Liver Transplantation at the Ochsner Clinic: Quality and Outcomes Improvement
- Liver Transplantation for "Very Early" Intrahepatic Cholangiocarcinoma: International Retrospective Study Supporting a Prospective Assessment
- Liver transplantation in a patient with Ehlers-Danlos syndrome
- Liver transplantation in hepatitis B core-negative recipients using livers from hepatitis B core-positive donors: A 13-year experience
- Liver Transplantation in Older Patients
- Liver transplantation in propionic and methylmalonic acidemia: A single center study with literature review
- Liver transplantation in the morbidly obese: Do the outcomes justify the use of scarce organs?
- LIVER TRANSPLANTATION IN THE SUPER MORBIDLY OBESE: A SINGLE CENTER EXPERIENCE; SECTION OF ABDOMINAL TRANSPLANTATION, OCHSNER CLINIC FOUNDATION, NEW ORLEANS, LA
- Liver Transplantation Using Hepatitis C Virus-Viremic Donors Into Hepatitis C Virus-Aviremic Recipients as Standard of Care